UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

SCHEDULE 14A

(Rule 14a-101)

INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Filed	by the	Registrant	X	Filed by a Party other than the Registrant	
	-	opropriate b			
	Prel	Preliminary Proxy Statement			
	Con	Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))			
	Defi	Definitive Proxy Statement			
\boxtimes	Defi	Definitive Additional Materials			
	Soli	iciting Material Pursuant to § 240.14a-12			
				ZIOPHARM Oncology, Inc.	
				(Name of Registrant as Specified in Its Charter)	
				(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)	
Paym	ent of l	Filing Fee (Check the a	appropriate box):	
\boxtimes	No fe	No fee required.			
	Fee o	Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.			
	(1)	Title of ea	ach class of	securities to which transaction applies:	
	(2)	Aggregate	e number of	f securities to which transaction applies:	
	(3)			r underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is now it was determined):	
	(4)	Proposed	maximum a	aggregate value of transaction:	
	(5)	Total fee paid:			
	Fee p	ee paid previously with preliminary materials:			
	Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.				
	(1)	Amount p	reviously p	aid:	
	(2)	Form, Sch	nedule or Re	egistration Statement No.:	
	(3)	Filing Par	rty:		
	(4)	Date Filed	d:		

*** Exercise Your Right to Vote ***

Important Notice Regarding the Availability of Proxy Materials for the Stockholder Meeting to Be Held on June 14, 2017

ZIOPHARM ONCOLOGY, INC.

Meeting Information

Meeting Type: Annual Meeting For holders as of: April 18, 2017

Date: June 14, 2017 **Time:** 10:00 AM EDT

Location: One First Avenue

Parris Building 34 Third Floor Navy Yard Plaza

Boston, Massachusetts 02129

ZIOPHARM ONCOLOGY, INC. ATTN: CORPORATE SECRETARY ONE FIRST AVENUE, PARRIS BLDG #34 THIRD FLOOR, NAVY YARD PLAZA BOSTON, MA 02129 You are receiving this communication because you hold shares in the above named company.

This is not a ballot. You cannot use this notice to vote these shares. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. You may view the proxy materials online at *www.proxyvote.com* or easily request a paper copy (see reverse side).

We encourage you to access and review all of the important information contained in the proxy materials before voting.

See the reverse side of this notice to obtain proxy materials and voting instructions.

— Before You Vote —

How to Access the Proxy Materials

Proxy Materials Available to VIEW or RECEIVE:

1. Notice & Proxy Statement 2. Form 10-K

How to View Online:

Have the information that is printed in the box marked by the arrow \Rightarrow [xxxx xxxx xxxx xxxx xxxx] (located on the following page) and visit: www.proxyvote.com.

How to Request and Receive a PAPER or E-MAIL Copy:

If you want to receive a paper or e-mail copy of these documents, you must request one. There is NO charge for requesting a copy. Please choose one of the following methods to make your request:

1) BY INTERNET: www.proxyvote.com 2) BY TELEPHONE: 1-800-579-1639

3) BY E-MAIL*: sendmaterial@proxyvote.com

* If requesting materials by e-mail, please send a blank e-mail with the information that is printed in the box marked by the arrow

** If requesting materials by e-mail, please send a blank e-mail with the information that is printed in the box marked by the arrow

** NOTE: The printed in the box marked by the arrow located on the following page) in the subject line.

Requests, instructions and other inquiries sent to this e-mail address will NOT be forwarded to your investment advisor. Please make the request as instructed above on or before May 31, 2017 to facilitate timely delivery.

— How To Vote —

Please Choose One of the Following Voting Methods

Vote In Person: Many stockholder meetings have attendance requirements including, but not limited to, the possession of an attendance ticket issued by the entity holding the meeting. Please check the meeting materials for any special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares.

Vote By Internet: To vote now by Internet, go to *www.proxyvote.com*. Have the information that is printed in the box marked by the arrow \rightarrow **xxxxxxxxxxx** available and follow the instructions.

Vote By Mail: You can vote by mail by requesting a paper copy of the materials, which will include a proxy card.

Voting items

The Board of Directors recommends you vote FOR the following:

1. Election of Directors

Nominees

01 Murray Brennan 02 James A. Cannon 03 Wyche Fowler, Jr. 04 Randal J. Kirk 05 Scott Tarriff 06 Michael Weiser

The Board of Directors recommends you vote FOR proposals 2 and 3.

- 2. To ratify the appointment of RSM US LLP as the Company's independent registered public accounting firm for 2017
- 3. To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement

The Board of Directors recommends you vote 1 YEAR on the following proposal:

4. To indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of the Company's named executive officers

NOTE: To transact any other business as may properly come before the meeting or any adjournments or postponements thereof.